Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
134,4 EUR | -1,76% | -0,07% | -3,46% |
03/07 | Johnson & Johnson's Rybrevant goedgekeurd door Health Canada voor de behandeling van gevorderde longkanker | MT |
02/07 | Momentum Picks Q3 2024: vijf aandelen voor de zomer |
Omzet 2024 * | 88,75 mld. 81,96 mld. | Omzet 2025 * | 92,26 mld. 85,21 mld. | Marktkapitalisatie | 351 mld. 324 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 3,95 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,8 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | 131.900 |
Dividendrendement 2024 * |
3,31% | Dividendrendement 2025 * |
3,46% | Vrij verhandelbaar | 77,08% |
Recentste transcriptie over Johnson & Johnson
1 dag | -1,78% | ||
1 week | -0,07% | ||
1 maand | +1,56% | ||
3 maanden | -3,96% | ||
6 maanden | -7,13% | ||
Lopend jaar | -3,46% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01-01-89 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01-01-98 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05-11-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25-04-19 |
D. Davis
BRD | Director/Board Member | 72 | 19-06-14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22-10-09 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-06-24 | 136,8 | -0,07% | 0 |
04-07-24 | 135,2 | +0,68% | 55 |
03-07-24 | 134,3 | -1,54% | 74 |
02-07-24 | 136,4 | -0,10% | 20 |
01-07-24 | 136,6 | -0,18% | 0 |
slotkoers Wiener Boerse, 28 juni 2024
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
+56,60% | 809 mld. | |
+39,52% | 624 mld. | |
+7,04% | 289 mld. | |
+13,74% | 240 mld. | |
+13,83% | 220 mld. | |
-0,49% | 219 mld. | |
+8,32% | 166 mld. | |
-2,85% | 157 mld. | |
+1,31% | 123 mld. |